Share This Page
Drug Price Trends for ALPRAZOLAM INTENSOL
✉ Email this page to a colleague
Average Pharmacy Cost for ALPRAZOLAM INTENSOL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALPRAZOLAM INTENSOL 1 MG/ML | 00054-3068-44 | 2.86900 | ML | 2025-10-22 |
| ALPRAZOLAM INTENSOL 1 MG/ML | 00054-3068-44 | 2.86900 | ML | 2025-09-17 |
| ALPRAZOLAM INTENSOL 1 MG/ML | 00054-3068-44 | 2.86900 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Alprazolam Intensol
What Is the Current Status of Alprazolam Intensol in the Pharmaceutical Market?
Alprazolam Intensol, a liquid formulation of the benzodiazepine alprazolam, is used predominantly for managing anxiety and panic disorders. It is FDA-approved and marketed by pharmaceutical companies, mainly as an alternative to tablet forms for patients with swallowing difficulties or specific dosing needs.
Regulatory and Patent Landscape
- Regulatory Approval: Approved in the U.S. and other markets; the FDA approved liquid formulations, including Intensol, to provide flexible dosing.
- Patent Status: The original patents on alprazolam expired in the mid-2000s, leading to generic competition. Specific formulations like Intensol may have trademarks or exclusivity periods depending on patent extensions or formulation patents.
Market Size and Growth Drivers
- Global Market: The global anxiolytics market was valued at approximately USD 4.2 billion in 2022, with benzodiazepines accounting for around 35%.
- U.S. Market: The U.S. accounts for roughly 60% of the global benzodiazepine sales, with an estimated market value of USD 2.5 billion in 2022.
- Growth Drivers: Increased prevalence of anxiety disorders, aging populations with swallowing difficulties, and demand for flexible dosing formulations drive growth.
Competitive Landscape
- Generic Competition: Multiple generic alprazolam products exist in tablet, solution, and suspension forms.
- Brand and Formulation Differences: While standard tablets dominate, liquid formulations like Intensol cater to specific patient needs and command premium pricing.
Price Analysis
| Formulation | Average Wholesale Price (AWP) (per mL) | Estimated Retail Price (per mL) |
|---|---|---|
| Alprazolam Intensol | USD 0.50 | USD 1.00 |
| Generic tablets | USD 0.05 - USD 0.10 | USD 0.10 - USD 0.25 |
- Pricing Premium: Intensol typically sells at a 4-10x premium over generic tablets, justified by formulation convenience and patient-specific dosing.
Market Trends Impacting Pricing
- Shift Toward Liquid Formulations: Increased demand for liquids in pediatric and geriatric care sustains premium pricing.
- Regulatory Constraints: Strict regulations around benzodiazepines influence prescribing patterns but do not significantly impact formulation prices.
- Reimbursement Policies: Insurance and Medicaid policies impact retail prices, with liquid formulations often receiving favorable coverage due to clinical advantages.
Price Projections (2023–2027)
| Year | Estimated Price per mL (retail) | Notes |
|---|---|---|
| 2023 | USD 1.00 | Base year; steady demand continues. |
| 2024 | USD 1.05 | Slight increase driven by inflation and manufacturing costs. |
| 2025 | USD 1.10 | Market stabilizes; no significant patent protections expiring. |
| 2026 | USD 1.15 | Emerging competition; minor erosion of premiums. |
| 2027 | USD 1.20 | Continued growth in liquid formulation demand; moderate price inflation. |
Supply Chain and Pricing Factors
- Manufacturing Costs: Production of liquid formulations involves complex processes and stabilization agents, maintaining higher costs than solids.
- Distribution: Limited distribution networks and compounded nature of the formulation impact pricing.
- Regulatory Compliance: Strict storage and handling regulations add to costs, partially reflected in retail prices.
Key Market Risks
- Generic Competition: Entry of new generics or biosimilars could pressure prices downward.
- Prescribing Trends: Shifts toward non-benzodiazepine anxiolytics or psychotherapies could reduce demand.
- Regulatory Changes: Stricter controls on benzodiazepine prescriptions may reduce overall market size.
Key Takeaways
- Alprazolam Intensol commands a significant premium over generic tablets due to formulation advantages.
- The U.S. market remains the primary revenue driver, with steady growth supported by demographic and clinical trends.
- Price projections suggest modest annual increases, limited by pricing pressures from generic entrants and changing prescribing guidelines.
- Supply chain complexities and regulatory costs sustain premium pricing but pose risks from increased competition.
FAQs
1. What distinguishes Alprazolam Intensol from other alprazolam formulations?
It is a liquid formulation designed for flexibility in dosing and ease of administration, particularly for patients who cannot swallow tablets.
2. How does regulatory status affect the pricing of Alprazolam Intensol?
Regulatory approval ensures market access, but existing patent protections influence pricing. Once patents expire, generic competition typically drives prices down.
3. Will the price of Alprazolam Intensol increase significantly in the next five years?
Projected increases are modest, around USD 0.05 to USD 0.10 per mL annually, due to inflation and demand, unless new patent protections or formulations emerge.
4. How does market competition influence the availability and price of liquid alprazolam?
Limited competition in the liquid formulation segment sustains higher prices, but entry of generic liquids could compress profit margins.
5. What are the primary factors influencing the demand for liquid alprazolam formulations?
Increased need among pediatric, geriatric, and hospitalized patients, along with preferences for flexible dosing, drive demand.
References
[1] Grand View Research. (2022). Anxiety Disorder Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Prescriptions Data.
[3] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[4] Statista. (2022). Benzodiazepine Market Revenue Worldwide.
[5] MarketWatch. (2023). Price Trends in Generic and Branded Pharmaceuticals.
More… ↓
